2002
DOI: 10.2174/1381612024607072
|View full text |Cite
|
Sign up to set email alerts
|

NR2B Selective NMDA Receptor Antagonists

Abstract: NR2B antagonists have received considerable attention in recent years. In this class of excitatory amino acid receptor antagonists NR2B antagonists have shown efficacy in neuroprotection, anti-hyperalgesic and anti-Parkinson animal models. Several groups are involved in developing these compounds as therapeutic agents and evaluating newer therapeutic targets for these agents. Until recently benzylpiperidine and phenylpiperidine templates, which were based on the structures of Ifenprodil and Eliprodil, formed t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
55
0

Year Published

2004
2004
2013
2013

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 91 publications
(55 citation statements)
references
References 0 publications
0
55
0
Order By: Relevance
“…Memantine demonstrates that clinical success can be achieved with NMDA antagonists of unique pharmacological characteristics. Another class of compounds that has gained attention as having such potential is the GluN2B subunit-selective NMDA receptor antagonists (Chazot, 2004;Gogas, 2006;Mony et al, 2009), for which a rich pharmacology exists (Chenard and Menniti, 1999;Nikam and Meltzer, 2002;McCauley, 2005;Layton et al, 2006). By blocking only one NMDA receptor subtype, these compounds could have therapeutic benefits but minimize on-target side effects.…”
Section: The Next Generation N-methyl-d-aspartate Receptor Antagonmentioning
confidence: 99%
“…Memantine demonstrates that clinical success can be achieved with NMDA antagonists of unique pharmacological characteristics. Another class of compounds that has gained attention as having such potential is the GluN2B subunit-selective NMDA receptor antagonists (Chazot, 2004;Gogas, 2006;Mony et al, 2009), for which a rich pharmacology exists (Chenard and Menniti, 1999;Nikam and Meltzer, 2002;McCauley, 2005;Layton et al, 2006). By blocking only one NMDA receptor subtype, these compounds could have therapeutic benefits but minimize on-target side effects.…”
Section: The Next Generation N-methyl-d-aspartate Receptor Antagonmentioning
confidence: 99%
“…The broad SAR governing these compound classes has typically involved two aromatic rings separated by a carbon linker that often contains nitrogen (Chenard and Menniti, 1999;Tamiz et al, 1999;Nikam and Meltzer, 2002;Borza and DomĂĄ ny, 2006;Layton et al, 2006). A variety of chemically distinct linkers and substituted aryl compounds retain activity, leading to considerable diversity in ligand structure.…”
Section: The Glun2b Amino-terminal Domain Harbors a Binding Site For mentioning
confidence: 99%
“…The NR2B subunit selective antagonists showed potency in animal models of neurodegeneration [99], Parkinson disease [155,156,200,220], and hyperalgesia [19,29,36,57]. It was also realized that this type of compounds lacks the serious side effects of the classic NMDAR antagonists' [162]. Although, like other un-competitive NMDAR antagonists they may have some adverse effect on learning and memory, it was proved that they have a wider separation between doses that are effective in seizure or stroke models and those that disrupt learning and memory.…”
Section: Nr2b Subunit Selective Nmdar Antagonistsmentioning
confidence: 99%